Prétraitement monodose d'obinutuzumab 7 jours avant le cycle 1 du glofitamab (atténuation du SCR)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-OBINUTUZUMAB |
|---|
| ID | REGIMEN-GLOFITAMAB-OBINUTUZUMAB-PRETREATMENT |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-05-01 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
Standalone authoring of the obinutuzumab single-dose pretreatment sub-regimen used to pre-deplete circulating CD20+ B-cells 7 days before glofitamab cycle 1 day 1. Mechanistically reduces CRS risk by shrinking the bispecific T-cell-engager substrate at first exposure; in NP30179 the combined obinutuzumab pretreatment + glofitamab step-up + corticosteroid premedication strategy held G≥3 CRS to ~4%. Sub-regimen entity authored separately for reuse across DLBCL / FL / future glofitamab combinations and to allow the renderer to surface the day -7 scheduling requirement as a distinct phase in patient-facing plans. Pair with parent schedule (REGIMEN-GLOFITAMAB-MONO-DLBCL-3L) starting 7 days later. Bibliographic record SRC-NP30179-DICKINSON-2022 is available; clinical claim linkage requires dual clinical sign-off.
Utilisé par
No reverse references found in the YAML corpus.